Tommy Lee Is Cyber Spying on Pammy! & other: August 2008

Sunday 31 August 2008

Peakdale Molecular Launches AssayReady4U(TM) In Collaboration With ChemPrintCo LLC

�AssayReady4U(TM) is an online based shopfront which allows drug
discovery researchers the ability to search, invention and blue-ribbon compounds from
a live physical solicitation of screening compounds. Then, using additional
options, build their final assay by selecting the exact measure and
assiduity required to perform their own unique experiments.

The final customer-selected compounds are cleanly and
accurately dispensed into SBS measure well plates of the customer's choosing
using ChemPrintCo's sophisticated and proprietary hydro-acoustic
technologies. Each AssayReady4U plate is sealed in an argon environment and
then vacuum-sealed in a moisture barrier bag and placed inside a
temperature-controlled pack for shipment. All orders are shipped from stock
within 24 hours of completion using a commercial carrier. Upon receipt, the
customer adds an set aside amount of solvent to reach the desired test
concentration.

Peakdale's collection is fundamentally rich in novel,
GPCR-targeted compounds. All compounds in the collection are selected for
their pertinency to GPCR research. Well-recognized ligand features are
combined with proprietorship scaffolds and monomers to produce a set of
screening compounds for GPCR hit discovery.

Glenn Killingworth, Director of Business Development at
Peakdale said: "I am frantic that we have reinforced this collaborationism in order
to reach out the smaller drug-research groups who don't want to build assets to
computer storage, handle and plate compounds, but but want to receive ready-to-screen
assays from a high quality collection, in on the nose the format that they need
to perform their drug discovery work."

Peakdale's Director of Technology Paul Doyle aforementioned: "This
represents an exciting new technology that allows a a great deal broader base of
researchers to access the world of various compounds in a cost effective
mode."

Adding to this, ChemPrintCo's Vice President of Sales Ron Jones said:
"The AssayReady4U(TM) products will be offered via an innovational web-based
one-stop shopping shopfront. The researchers will effortlessly select
compounds, assay test concentration, plate format, plate manufacturer and
controls with a few clicks of a mouse thus optimizing their valuable time for
research."

�About Peakdale Molecular

Peakdale Molecular was founded in 1992. Today the company's
customers include the majority of the major spherical pharmaceutical businesses
and a rapidly growing base of biotechnology companies worldwide. Peakdale's
teams of chemists combine experience in pharmaceutical R&D, medicinal
chemistry, parallel synthesis, process developing and fine chemicals to
deliver singular chemistry solutions to a range of drug discovery challenges.
Peakdale has growing capabilities in computational alchemy, analytical
alchemy and ADME screening.

The application of less unremarkably used chemistry, including
high gear temperature/pressure reactions, proprietary heterocyclic compound chemistry and
nucleoside synthesis, enables Peakdale's chemists to generate unique
compounds for drug discovery. Peakdale operates in several distinct markets
providing novel screening compounds, targeted covering libraries, catalogue
intermediates, custom synthesis and contract research. Further information
about the company can be obtained at hTTP://www.peakdale.com

About ChemPrintCo LLC

ChemPrintCo is a privately held ship's company located in the pump
of Silicon Valley and the Bay Area's deep biotech and pharmaceutical
community. The management team has been together for all over 15 days developing
unique and cost-efficient products and systems for the biotech and
high tech industries. Their mission is to address the needs of the
individual scientific researcher with ready-to-use assays in a single-use
easily plate format. We carry out this by giving each researcher the ability
to select compounds from starring suppliers in the exact amount and
concentration required to perform their possess unique experiments.

Peakdale Molecular

More info

Thursday 21 August 2008

Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer

�UroToday.com - Dr. Arto Salonen and Finnish colleagues compared intermittent androgen privation (IAD) to continuous androgenic hormone deprivation (CAD) in 856 patients with locally advanced or metastatic prostate cancer (CaP) treated at 27 clinics in Finland. This report represents an meantime analysis of their data.

The patients were accrued between 1997 and 2003 and had a life expectancy of at least 12 months. A 24 week flow in of continuous LHRH agonist therapy preceded randomisation for those who had a PSA decrease to

Mean patient role age was 72 days and hateful PSA at entry was 383ng/ml. Patients had point T3 tumors (61%) and stage T4 tumors (29%). A come of 564 men completed the row period and 279 were randomized to IAD and 285 to CAD. PSA, alkaline phosphatase, proportion of T4 tumors, poorly differentiated tumors, metastatic disease, and skeletal hot spots among patients with M1 disease were significantly higher in the IAD group. Baseline testosterone was not important in the analysis.

A significant proportion of patients with the most fast-growing and advance CaP did not reply to androgenic hormone deprivation therapy. The investigators concluded that IAD appears feasible for patients with locally advanced, hormone sore CaP. A low limit of testosterone at baseline did non select for IAD or CAD. Patients with advanced CaP, with a high PSA, alkaline phosphatase and metastatic disease, with more than 5 skeletal hot spots, did not read adequate biochemical response to ADT. Thus, they ar not good candidates for IAD and other modalities should be considered.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL

J Urol. 2008 Jul 15. Epub ahead of print.

doi:10.1016/j.juro.2008.05.009

Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content scripted by world urology winder opinion leadership actively intermeshed in clinical practice.

To access the in vogue urology word releases from UroToday, go to:
www.urotoday.com

Copyright � 2008 - UroToday

More information